Stephen Worsley

Stephen Worsley has a diverse work experience in the biopharmaceutical industry. Stephen is currently serving as the Chief Business Officer at Lytix Biopharma, a clinical stage biotech company developing novel cancer immunotherapies. Prior to this, Stephen worked as the Managing Director at Miramonte Capital Advisors, where they provided corporate development and fundraising consultancy services for emerging biotechs. Stephen also held the position of Vice President Strategic Business Development at Redwood Biosciences/Catalent Pharma Solutions, where they played a key role in developing next-generation antibody-drug conjugate (ADC) technology for hard-to-treat cancers. Stephen's experience includes serving as the Chief Business Officer at Sutro Biopharma, a drug discovery and development company, and as the Senior Vice President of Business Development at Indi Molecular, specializing in synthetic small peptides for therapeutic applications. Stephen has also held executive positions at Avid Bioservices, Peregrine Pharmaceuticals, Centrose Pharmaceutical, and Zosano Pharma, where they contributed to the development of various biopharmaceutical technologies. Stephen's expertise lies in business development, strategic planning, and licensing strategies in the field of oncology therapeutics.

Stephen Worsley attended Acalanes High School, although the specific duration of their studies at the high school is not provided. Stephen then pursued a Bachelor of Science degree in Economics, with a minor in Chemistry, at the University of Utah from 1981 to 1986. Later, from 1988 to 1990, they pursued a Master of Business Administration (MBA) degree with a focus on Finance at the University of Washington.